Sales of new products at AstraZeneca Plc increased faster, and generated more revenue than legacy medicines in the third quarter and 2018 first nine months, leading the UK company to declare it had reached a turning point on the way towards sustainable growth.
“This is the start of a period of sustained growth in the years to come,” Pascal Soriot, the chief executive, told journalists during a quarterly news conference on 8 November. He confirmed the company’s forecast for a low single-digit percentage increase in product sales this year.